Abstract:The cGAS STING pathway has received much attention in recent years, and it has been recognized as an important component of the innate immune response. Since the discovery of STING and that of cGAS, many observations based on preclinical models suggest that the faulty regulation of this pathway is involved in many type I IFN autoinflammatory disorders. Evidence has been accumulating that cGAS/STING might play an important role in pathologies beyond classical immune diseases, as in, for example, cardiac failure. Human genetic mutations that result in the activation of STING or that affect the activity of cGAS have been demonstrated as the drivers of rare interferonopathies affecting young children and young adults. Nevertheless, no data is available in the clinics demonstrating the therapeutic benefit in modulating the cGAS/STING pathway. This is due to the lack of STING/cGAS-specific low molecular weight modulators that would be qualified for clinical exploration. The early hopes to learn from STING agonists, which have reached the clinics in recent years for selected oncology indications, have not yet materialized since the initial trials are progressing very slowly. In addition, transforming STING agonists into potent selective antagonists has turned out to be more challenging than expected. Nevertheless, there has been progress in identifying novel low molecular weight compounds, in some cases with unexpected mode of action, that might soon move to clinical trials. This study gives an overview of some of the potential indications that might profit from modulation of the cGAS/STING pathway and a short overview of the efforts in identifying STING modulators (agonists and antagonists) suitable for clinical research and describing their potential as a “drug”.

Agonists and Inhibitors of the Cgas-Sting Pathway

cGAS-STING signaling pathway in gastrointestinal inflammatory disease and cancers

Lysosomal Control of the Cgas-Sting Signaling.

Development of small molecule inhibitors/agonists targeting STING for disease

Cgas-Sting, an Important Pathway in Cancer Immunotherapy.

cGAS-STING pathway in cancer biotherapy

Bioactive Modulators Targeting STING Adaptor in Cgas-Sting Pathway

The Cgas-Sting Pathway: Post-translational Modifications and Functional Implications in Diseases

Agonists and Inhibitors of the STING Pathway: Potential Agents for Immunotherapy

The cGAS/STING Pathway: A Novel Target for Cancer Therapy

Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy

STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Cgas–sting, an Important Signaling Pathway in Diseases and Their Therapy

Medicinal chemistry perspective on cGAS-STING signaling pathway with small molecule inhibitors

Insight into the Dichotomous Regulation of STING Activation in Immunotherapy

2 ',3 '-Cyclic GMP-AMP Dinucleotides for STING-Mediated Immune Modulation: Principles, Immunotherapeutic Potential, and Synthesis

Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response

The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges

cGAS-STING signaling in cancer immunity and immunotherapy

Cancer Immunotherapy Strategies That Target the Cgas-Sting Pathway.